Not available
Quote | Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Last: | $41.79 |
---|---|
Change Percent: | -1.69% |
Open: | $40.2 |
Close: | $41.79 |
High: | $42.4 |
Low: | $39.57 |
Volume: | 641,668 |
Last Trade Date Time: | 03/27/2024 03:00:00 am |
News | Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica...
Message Board Posts | Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Subject | By | Source | When |
---|---|---|---|
$RYTM what do you make of this data? | grich1 | investorshub | 04/27/2023 2:46:30 AM |
Do we have a winner?Turn around time? | Amatuer17 | investorshub | 04/19/2023 9:26:37 PM |
should we be shorting? | midastouch017 | investorshub | 04/17/2023 6:06:09 PM |
$RYTM The gaining up | Amatuer17 | investorshub | 04/16/2023 9:29:03 PM |
$RYTM MomentumIts trading up | bandit007 | investorshub | 04/15/2023 1:05:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica...
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on t...
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two ...